TARDBP and amyotrophic lateral sclerosis: In this study, we used the in vivo fly model of ALS to assess the effectiveness of the MEKi trametinib, which substantially suppressed TDP-43-mediated immune overactivation and markedly mitigated TDP-43-induced motor deficits.